Harrow entered into an agreement to acquire Melt Pharmaceuticals and plans to submit a new drug application for MELT-300, Melt’s lead candidate, to the FDA in 2027.
“MELT-300 integrates seamlessly into Harrow’s existing commercial infrastructure, specifically our surgical team, which calls on and has established relationships with ophthalmologists,” Mark L. Baum, CEO of Harrow, told Healio. “The initial focus will be offering those 700+ accounts who purchased over 150,000 MKO Melts from ImprimisRx last year an FDA-approved and potentially reimbursable product. Knowing precisely which